For $45 million upfront, Vor Bio is gaining ex-China rights to RemeGen’s telitacicept, a first-in-class recombinant ...

A little less than a year after topping up its medical countermeasure contracts with Emergent BioSolutions, the federal ...

U.S. multinational company Abbott entered a partnership with Abu Dhabi's Department of Health to manufacture medicines in the ...

After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...

While the first meeting of Robert F. Kennedy Jr.’s reshuffled Advisory Committee on Immunization Practices (ACIP) didn’t ...

In opening Wednesday’s meeting, newly appointed ACIP chair Martin Kulldorff, Ph.D., leaned into the controversy surrounding U ...

What kind of uptake can Gilead Sciences expect for its highly touted, long-acting HIV pre-exposure prophylaxis (PrEP) ...

Approved eight months ago for a certain class of patients with both hemophilia A or B, Pfizer’s Hympavzi has now shown its effectiveness in another group of patients with the bleeding disorder. | ...

Saatchi & Saatchi Wellness announced Wednesday the appointments of three new leaders: Brendan Gallagher as president, Divya Dileep as chief creative officer and Beth Bour as the agency’s first-ever ...

As part of a multi-year collaboration, GSK and India’s Bharat Biotech are redoubling their efforts to bring the world’s first malaria vaccine to more countries in need at affordable prices. | The ...

In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, ...

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect ...